ARAV Aravive

Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference

Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference

HOUSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the 2021 BTIG Biotechnology Conference on August 9, 2021, at 9:30 AM ET. Aravive will also be participating in one-on-one meetings at the conference.

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative if you have interest.

About Aravive

Aravive, Inc. is a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases. Aravive’s lead therapeutic, AVB-500, is a first-in-class ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth, tumor metastasis, resistance to treatment and decreased survival. AVB-500 has the potential to be combined with multiple anti-cancer therapies across several tumor types, due to its novel mechanism of action and favorable safety profile. AVB-500 has been granted Fast Track Designation by the U.S. Food and Drug Administration in platinum resistant recurrent ovarian cancer. The Company is currently evaluating AVB-500 in a registrational Phase 3 trial in platinum resistant ovarian cancer and a Phase 1b/2 trial in clear cell renal cell carcinoma. Aravive plans to initiate a Phase 1b/2 trial evaluating AVB-500 in first-line treatment of pancreatic cancer in the second half of 2021. The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. For more information, please visit www.aravive.com.

Contact:

Joseph T. Schepers

VP, Investor Relations, Aravive, Inc.

[email protected]

(770) 558-5517



EN
27/07/2021

Underlying

ARAVAravive

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aravive

 PRESS RELEASE
Free
ARAV ARAVIVE

Aravive, Inc. to Delist from The Nasdaq Stock Market

Aravive, Inc. to Delist from The Nasdaq Stock Market HOUSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), announced today that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market (“Nasdaq”)  and, based upon ownership of its shares by fewer than 300 holders of record, deregister its common stock under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and suspend its public reporting obligations. As previously disclosed, at the Company’s 2023 annual stockholder’s meeting, the s...

January 17, 2024 1 EN
 PRESS RELEASE
Free
ARAV ARAVIVE

Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of B...

Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer Trial did not meet primary endpoint of progression-free survivalCash at the end of Q2 of approximately $18M (unaudited) is expected to be sufficient to fund operations into early Q4 2023 HOUSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that its Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept...

August 2, 2023 1 EN
 PRESS RELEASE
Free
ARAV ARAVIVE

Aravive to Present Updated Clinical Data from Batiraxcept Trials in Re...

Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023 HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the acceptance of two abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held October 20-24, 2023 in Madrid, Spain. Posters will feature clinical data from the Company’s ongoing Phase 1b/2 trials of batiraxcept in cl...

July 28, 2023 1 EN
 PRESS RELEASE
Free
ARAV ARAVIVE

Aravive to Participate in William Blair’s Innovator Series: Transition...

Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023 HOUSTON, July 14, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer will be participating in a fireside chat at the William Blair Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success being held virtually on July 18, 2023. William Blair...

July 14, 2023 1 EN
 PRESS RELEASE
Free
ARAV ARAVIVE

Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)

Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c) HOUSTON, June 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that in accordance with Nasdaq rules regarding employment inducement awards, the Company has granted an equity compensation award to a new employee. The Compensation Committee of ARAV’s Board of Directors approved the award of options to purchase an aggregate of 40,000 shares of common stock, with a grant date of June 8,...

June 13, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch